Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated

M Fukutomi1, S Kobayashi, K Niwaya

  • 1Department of Surgery III, Nara Medical College, Japan.

Artificial Organs
|July 1, 1996
PubMed

Insights

Heparin-coated cardiopulmonary bypass (CPB) systems significantly reduce platelet, granulocyte, and complement activation. This biocompatible approach also lowers postoperative blood loss in patients undergoing cardiac surgery.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Surgery
  • Materials Science

Background:

  • Cardiopulmonary bypass (CPB) systems can trigger inflammatory responses, affecting platelets, granulocytes, and complement activation.
  • Improving the biocompatibility of CPB circuits is crucial for reducing complications during cardiac surgery.

Purpose of the Study:

  • To investigate the impact of heparin-coated CPB systems on inflammatory markers and clinical outcomes.
  • To compare the effects of a fully heparin-coated CPB system versus a partially coated system and an uncoated system.

Main Methods:

  • A comparative study involving 30 patients undergoing coronary artery bypass surgery.
  • Three groups were analyzed: fully heparin-coated CPB (HC), heparin-coated oxygenator with uncoated circuit (HO), and uncoated CPB (UC).
  • Measurements included plasma C3a, C4a, granulocyte elastase, beta-thromboglobulin, platelet counts, and postoperative blood loss.

Main Results:

  • The heparin-coated CPB system (HC) significantly reduced complement activation (C3a, C4a) and granulocyte activation (elastase) compared to uncoated systems.
  • The HC group showed significantly higher platelet counts and lower beta-thromboglobulin levels, indicating reduced platelet activation.
  • Postoperative blood loss was significantly lower in the HC group compared to the uncoated group.

Conclusions:

  • Heparin coating of the entire CPB circuit enhances biocompatibility by mitigating inflammatory responses.
  • The HC CPB system effectively reduces platelet, granulocyte, and complement activation.
  • This improved biocompatibility translates to reduced postoperative bleeding, highlighting the clinical benefits of heparin-coated CPB systems.

Related Concept Videos

Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...